Clinical Trials Directory

A Phase I/II, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis.

This study seeks to (i) determine a safe and tolerated dose of CYT387 given to patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of orally-administered CYT387 as a treatment for PMF, post-PV or post-ET.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : CYT387

Phase: Phase 1/Phase 2


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Diagnosis of PMF or post-polycythemia Vera (PV) or post-essential Thrombocythemia (ET) MF as per revised World Health Organization (WHO) criteria. - High-risk or Intermediate-2 risk MF (as defined by the International Prognostic Scoring System [IPSS]; Appendix 13.6); or intermediate-I risk MF (IPSS) associated with symptomatic splenomegaly/hepatomegaly and/or unresponsive to available therapy. - Must be at least 18 years of age with life expectancy of ? 12 weeks. - Must be able to provide informed consent and be willing to sign an informed consent form. - Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. - Must have evidence of acceptable organ function within 7 days of initiating study drug as evidenced by the following: - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ? 2.5 x upper limit of normal (ULN) (or ? 5 x ULN if in the investigator's opinion the elevation is due to extramedullary hematopoiesis) - Bilirubin ? 2.0 x ULN or direct bilirubin < 1.0 - Serum creatinine ? 2.5 x ULN - Absolute neutrophil count ? 500/ÁL - Platelet count ? 50,000/ÁL - Females of childbearing potential must have a negative pregnancy test within 4 days of initiating study drug.

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting

Footer Links: